Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 3/2012

01.12.2012 | Original Article

Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer

verfasst von: Annette Wunderlich, Silvia Roth, Annette Ramaswamy, Brandon H. Greene, Cornelia Brendel, Ulrike Hinterseher, Detlef K. Bartsch, Sebastian Hoffmann

Erschienen in: Endocrine | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Conventional treatment by surgery, radioiodine, and thyroxin-suppressive therapy often fails to cure anaplastic thyroid cancer (ATC). Therefore several attempts have been made to evaluate new therapy options by use of “small molecule inhibitors”. ATC was shown to respond to monotherapeutic proteasome and Aurora kinase inhibition in vitro as well as in xenotransplanted tumor cells. Aim of this study was to evaluate the effect of combined treatment targeting the ubiquitin–proteasome system by bortezomib and Aurora kinases by use of MLN8054. Three ATC cell lines (Hth74, C643, and Kat4.1) were used. The antiproliferative effect of combined treatment with bortezomib and MLN8054 was assessed by MTT-assay and cell cycle analysis (FACS). Proapoptotic effects were evaluated by measurement of Caspase-3 activity, and effects on VEGF secretion were analyzed by ELISA. Compared to mono-application combined treatment with bortezomib and MLN8054 resulted in a further decrease of cell density, whereas antagonizing effects were found regarding cell cycle progression. Caspase-3 activity was increased up to 2.7- and 14-fold by mono-application of MLN8054 and bortezomib, respectively. When the two drugs were used in combination, a further enhancement of Caspase-3 activity was achieved, depending on the cell line. VEGF secretion was decreased following bortezomib treatment and remained unchanged by MLN8054. Only in C643 cells, the bortezomib-induced down-regulation was enhanced when MLN8054 was applied simultaneously. In conclusion, our data demonstrate that targeting the proteasome and Aurora kinases simultaneously results in additional antitumoral effects in vitro, especially regarding cell growth and induction of apoptosis. The efficacy of this therapeutic approach remains to be revised by in vivo and clinical application.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
B.H. Lang, C.Y. Lo, Surgical options in undifferentiated thyroid carcinoma. World J. Surg. 31(5), 969–977 (2007)PubMedCrossRef
2.
B. Aschebrook-Kilfoy, M.H. Ward, M.M. Sabra, S.S. Devesa, Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 21(2), 125–134 (2011)PubMedCrossRef
3.
R.C. Smallridge, L.A. Marlow, J.A. Copland, Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16(1), 17–44 (2009)PubMedCrossRef
4.
J.A. Woyach, M.H. Shah, New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 16(3), 715–731 (2009)PubMedCrossRef
5.
H.T. Ha, J.S. Lee, S. Urba, R.J. Koenig, J. Sisson, T. Giordano, F.P. Worden, A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20(9), 975–980 (2010)PubMedCrossRef
6.
C.J. Mooney, G. Nagaiah, P. Fu, J.K. Wasman, M.M. Cooney, P.S. Savvides, J.A. Bokar, A. Dowlati, D. Wang, S.S. Agarwala, S.M. Flick, P.H. Hartman, J.D. Ortiz, P.N. Lavertu, S.C. Remick, A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19(3), 233–240 (2009)PubMedCrossRef
7.
M.M. Cooney, J. Ortiz, R.M. Bukowski, S.C. Remick, Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr. Oncol. Rep. 7(2), 90–95 (2005)PubMedCrossRef
8.
W.K. Wu, C.H. Cho, C.W. Lee, K. Wu, D. Fan, J. Yu, J.J. Sung, Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 293(1), 15–22 (2010)PubMedCrossRef
9.
10.
C.S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K.B. Ain, N. Mitsiades, Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab. 91(10), 4013–4021 (2006)PubMedCrossRef
11.
C. Conticello, L. Adamo, R. Giuffrida, L. Vicari, A. Zeuner, A. Eramo, G. Anastasi, L. Memeo, D. Giuffrida, G. Iannolo, M. Gulisano, R. De Maria, Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J. Clin. Endocrinol. Metab. 92(5), 1938–1942 (2007)PubMedCrossRef
12.
F. Stenner, H. Liewen, M. Zweifel, A. Weber, J. Tchinda, B. Bode, P. Samaras, S. Bauer, A. Knuth, C. Renner, Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 99(9), 1847–1852 (2008)PubMed
13.
R. Sorrentino, S. Libertini, P.L. Pallante, G. Troncone, L. Palombini, V. Bavetsias, D. Spalletti-Cernia, P. Laccetti, S. Linardopoulos, P. Chieffi, A. Fusco, G. Portella, Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. 90, 928–935 (2005)PubMedCrossRef
14.
Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.G. Delcros, M. Toller, F. Curcio, F.S. Ambesi-Impiombato, M. D’Armiento, S. Ulisse, Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr. Relat. Cancer 15, 559–568 (2008)PubMedCrossRef
15.
A. Wunderlich, M. Fischer, T. Schlosshauer, A. Ramaswamy, B.H. Greene, C. Brendel, D. Doll, D. Bartsch, S. Hoffmann, Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci. 102(4), 746–756 (2011)CrossRef
16.
N.E. Heldin, B. Westermark, The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 3, 127–131 (1991)PubMed
17.
K.B. Ain, S. Tofiq, K.D. Taylor, Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J. Clin. Endocrinol. Metab. 81, 3650–3653 (1999)CrossRef
18.
S. Hoffmann, S. Gläser, A. Wunderlich, S. Lingelbach, C. Dietrich, A. Burchert, H. Müller, M. Rothmund, A. Zielke, Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors—a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch. Surg. 391(6), 589–596 (2006)PubMedCrossRef
19.
M.C. Berenbaum, Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 3, 269–335 (1981)CrossRef
20.
A. Wunderlich, T. Arndt, M. Fischer, S. Roth, A. Ramaswamy, BH. Greene, C. Brendel, U. Hinterseher, K. Detlef, DK. Bartsch, S. Hoffmann, Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J. Surg. Oncol. 105(4), 357–364 (2012). doi:10.​1002/​jso.​22113
21.
J.A. Woyach, M.H. Shah, New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 3, 715–731 (2009)CrossRef
22.
C.S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K.B. Ain, N. Mitsiades, Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab. 91(10), 4013–4021 (2006)PubMedCrossRef
23.
S. Libertini, A. Abagnale, C. Passaro, G. Botta, S. Barbato, P. Chieffi, G. Portella, AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr. Relat. Cancer 18(1), 129–141 (2011)PubMedCrossRef
24.
M.G. Manfredi, J.A. Ecsedy, K.A. Meetze, S.K. Balani, O. Burenkova, W. Chen, K.M. Galvin, K.M. Hoar, J.J. Huck, P.J. LeRoy, E.T. Ray, T.B. Sells, B. Stringer, S.G. Stroud, T.J. Vos, G.S. Weatherhead, D.R. Wysong, M. Zhang, J.B. Bolen, C.F. Claiborne, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. USA 104, 4106–4111 (2007)PubMedCrossRef
25.
G. Görgün, E. Calabrese, T. Hideshima, J. Ecsedy, G. Perrone, M. Mani, H. Ikeda, G. Bianchi, Y. Hu, D. Cirstea, L. Santo, Y.T. Tai, S. Nahar, M. Zheng, M. Bandi, R.D. Carrasco, N. Raje, N. Munshi, P. Richardson, K.C. Anderson, A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115(25), 5202–5213 (2010)PubMedCrossRef
26.
J.M. Negri, D.W. McMillin, J. Delmore, N. Mitsiades, P. Hayden, S. Klippel, T. Hideshima, D. Chauhan, N.C. Munshi, C.A. Buser, J. Pollard, P.G. Richardson, K.C. Anderson, C.S. Mitsiades, In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br. J. Haematol. 147(5), 672–676 (2009)PubMedCrossRef
27.
D. Baiz, G. Pozzato, B. Dapas, R. Farra, B. Scaggiante, M. Grassi, L. Uxa, C. Giansante, C. Zennaro, G. Guarnieri, G. Grassi, Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 91(3), 373–382 (2009)PubMedCrossRef
28.
Y. Wang, A.K. Rishi, V.T. Puliyappadamba, S. Sharma, H. Yang, A. Tarca, Q. Ping Dou, F. Lonardo, J.C. Ruckdeschel, H.I. Pass, A. Wali, Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother. Pharmacol. 66(3), 455–466 (2010)PubMedCrossRef
29.
A. Brüning, P. Burger, M. Vogel, M. Rahmeh, K. Friese, M. Lenhard, A. Burges, Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Investig. New Drugs 27(6), 543–551 (2008)CrossRef
30.
S.E. Canfield, K. Zhu, S.A. Williams, D.J. McConkey, Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol. Cancer Ther. 5(8), 2043–2050 (2006)PubMedCrossRef
31.
S.T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, D.J. McConkey, The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 3(1), 59–70 (2004)PubMed
32.
N. Keen, S. Taylor, Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4(12), 927–936 (2004)PubMedCrossRef
33.
P. Kaestner, A. Stolz, H. Bastians, Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol. Cancer Ther. 8(7), 2046–2056 (2009)PubMedCrossRef
34.
J.J. Huck, M. Zhang, A. McDonald, D. Bowman, K.M. Hoar, B. Stringer, J. Ecsedy, M.G. Manfredi, M.L. Hyer, MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 8(3), 373–384 (2010)PubMedCrossRef
35.
S. Fujioka, G.M. Sclabas, C. Schmidt, W.A. Frederick, Q.G. Dong, J.L. Abbruzzese, D.B. Evans, C. Baker, P.J. Chiao, Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res. 9(1), 346–354 (2003)PubMed
36.
J. Zhang, B. Peng, in vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. BMC Cancer. 7, 95 (2007)
37.
A.M. Roccaro, T. Hideshima, N. Raje, S. Kumar, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Ribatti, B. Nico, A. Vacca, F. Dammacco, P.G. Richardson, K.C. Anderson, Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66(1), 184–191 (2006)PubMedCrossRef
38.
S. Greenberger, I. Adini, E. Boscolo, J.B. Mulliken, J. Bischoff, Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 13(4), 327–335 (2010)PubMedCrossRef
39.
L.X. Xue, M. Jiang, L.Q. Xie, C.G. Ruan, Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18(3), 744–748 (2010)PubMed
40.
L.X. Xue, M. Jiang, L.Q. Xie, C.G. Ruan, The effect of bortezomib on migration of endothelial cells and angiogenesis. Zhonghua Xue Ye Xue Za Zhi. 31(6), 403–406 (2010)PubMed
41.
R. LeBlanc, L.P. Catley, T. Hideshima, S. Lentzsch, C.S. Mitsiades, N. Mitsiades, D. Neuberg, O. Goloubeva, C.S. Pien, J. Adams, D. Gupta, P.G. Richardson, N.C. Munshi, K.C. Anderson, Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62(17), 4996–5000 (2002)PubMed
42.
C. Brignole, D. Marimpietri, F. Pastorino, B. Nico, D. Di Paolo, M. Cioni, F. Piccardi, M. Cilli, A. Pezzolo, M.V. Corrias, V. Pistoia, D. Ribatti, G. Pagnan, M. Ponzoni, Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J. Natl. Cancer Inst. 98(16), 1142–1157 (2006)PubMedCrossRef
43.
J.B. Hamner, P.V. Dickson, T.L. Sims, J. Zhou, Y. Spence, C.Y. Ng, A.M. Davidoff, Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 142(2), 185–191 (2007)PubMedCrossRef
44.
L. Zhang, S. Zhang, ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J. Obstet. Gynaecol. Res. 37(6), 591–600 (2011)PubMedCrossRef
Metadaten
Titel
Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer
verfasst von
Annette Wunderlich
Silvia Roth
Annette Ramaswamy
Brandon H. Greene
Cornelia Brendel
Ulrike Hinterseher
Detlef K. Bartsch
Sebastian Hoffmann
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9665-4

Weitere Artikel der Ausgabe 3/2012

Endocrine 3/2012 Zur Ausgabe

Original Article

Elevated A1C is associated with impaired early-phase insulin secretion rather than insulin resistance in Koreans at high risk for developing diabetes

Letter to the Editor

Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin

Original Article

Mutations in the AVPR2, AVP-NPII, and AQP2 genes in Turkish patients with diabetes insipidus

Erratum

Erratum to: Elevated A1C is associated with impaired early-phase insulin secretion rather than insulin resistance in Koreans at high risk for developing diabetes

Research Letter

Genetic determinants and early carotid atherosclerosis: is there a role for the ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP-1) K121Q polymorphism? Preliminary results in non diabetic individuals

Original Article

Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise